“After hopefully demonstrating efficacy through the pilot study, Conboy says that plans are underway for a 200–300 person, placebo-controlled Phase 3 trial to prove the use of the plasma dilution as a technology that innovatively treats co-morbidities of aging.”
This could be the first bridge.
UC Berkeley’s Irina Conboy talks parabiosis, plasma dilution, and why young blood may not hold the all answers.
Comments are closed.